Search

Your search keyword '"Alibhai, Shabbir M H"' showing total 712 results
Start Over Author "Alibhai, Shabbir M H"
712 results on '"Alibhai, Shabbir M H"'

1. Prostate Cancer

Author

Herrera-Caceres, Jaime O., Fleshner, Neil, Alibhai, Shabbir M. H., Shahrokni, Armin, Section editor, Wasserman, Michael R., editor, Bakerjian, Debra, editor, Linnebur, Sunny, editor, Brangman, Sharon, editor, Cesari, Matteo, editor, and Rosen, Sonja, editor

Published
2024
Full Text
View/download PDF

4. Geriatric assessment for older people with cancer: policy recommendations

Author

Seghers, P. A. L., Alibhai, Shabbir M. H., Battisti, Nicolò Matteo Luca, Kanesvaran, Ravindran, Extermann, Martine, O’Donovan, Anita, Pilleron, Sophie, Mislang, Anna Rachelle, Musolino, Najia, Cheung, Kwok-Leung, Staines, Anthony, Girvalaki, Charis, Soubeyran, Pierre, Portielje, Johanneke E. A., Rostoft, Siri, Hamaker, Marije E., Trépel, Dominic, and O’Hanlon, Shane

Published
2023
Full Text
View/download PDF

7. Prostate Cancer

Author

Herrera-Caceres, Jaime O., primary, Fleshner, Neil, additional, and Alibhai, Shabbir M. H., additional

Published
2023
Full Text
View/download PDF

13. Geriatric Surgical Oncology

Author

Chesney, Tyler R., AlQurini, Naser, Alibhai, Shabbir M. H., Wright, Frances C., editor, Escallon, Jaime M., editor, Cukier, Moises, editor, Tsang, Melanie E., editor, and Hameed, Usmaan, editor

Published
2020
Full Text
View/download PDF

15. Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals

Author

Campbell, Kristin L., Cormie, Prue, Weller, Sarah, Alibhai, Shabbir M. H., Bolam, Kate A., Campbell, Anna, Cheville, Andrea L., Dalzell, Mary-Ann, Hart, Nicolas H., Higano, Celestia S., Lane, Kirstin, Mansfield, Sami, McNeely, Margaret L., Newton, Robert U., Quist, Morten, Rauw, Jennifer, Rosenberger, Friederike, Santa Mina, Daniel, Schmitz, Kathryn H., Winters-Stone, Kerri M., Wiskemann, Joachim, and Goulart, Jennifer

Published
2021
Full Text
View/download PDF

16. Access to cancer clinical trials for racialised older adults: an equity-focused rapid scoping review protocol

Author

Li, Vivian, primary, Alibhai, Shabbir M H, additional, Noel, Kenneth, additional, Fazelzad, Rouhi, additional, Haase, Kristin, additional, Mariano, Caroline, additional, Durbano, Sara, additional, Sattar, Schroder, additional, Newton, Lorelei, additional, Dawe, David, additional, Bell, Jennifer A, additional, Hsu, Tina, additional, Wong, Sabrina T, additional, Lofters, Aisha, additional, Bender, Jacqueline L, additional, Manthorne, Jackie, additional, and Puts, Martine T E, additional

Published
2024
Full Text
View/download PDF

25. Effectiveness of geriatric assessment and management in older cancer patients: a systematic review and meta-analysis.

Author

Anwar, Mohammed Rashidul, Yeretzian, Shant Torkom, Ayala, Ana Patricia, Matosyan, Emma, Breunis, Henriette, Bote, Kathyrin, Puts, Martine, Habib, Mohammed Hassan, Li, Qixuan, Sahakyan, Yeva, Alibhai, Shabbir M H, and Abrahamyan, Lusine

Subjects
GERIATRIC assessment, OLDER patients, CANCER patients, TERMINATION of treatment, CANCER patient care
Abstract

Background Frailty and multimorbidity among older cancer patients affect treatment tolerance and efficacy. Comprehensive geriatric assessment and management is recommended to optimize cancer treatment, but its effect on various outcomes remains uncertain. Objective Our objective was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) and cost-effectiveness studies comparing comprehensive geriatric assessment (with or without implementation of recommendations) to usual care in older cancer patients. Methods We searched MEDLINE, EMBASE, CINAHL, and Cochrane trials from inception to January 27, 2023, for RCTs and cost-effectiveness studies. Pooled estimates for outcomes were calculated using random-effects models. Results A total of 19 full-text articles representing 17 RCTs were included. Average participant age was 72-80 years, and 31%-62% were female. Comprehensive geriatric assessment type, mode of delivery, and evaluated outcomes varied across studies. Meta-analysis revealed no difference in risk of mortality (risk ratio [RR] = 1.08. 95% confidence interval [CI] = 0.91 to 1.29), hospitalization (RR = 0.92, 95% CI = 0.77 to 1.10), early treatment discontinuation (RR = 0.89, 95% CI = 0.67 to 1.19), initial dose reduction (RR = 0.99, 95% CI = 0.99 to 1.26), and subsequent dose reduction (RR = 0.87, 95% CI = 0.70 to 1.09). However, the risk of treatment toxicity was statistically significantly lower in the comprehensive geriatric assessment group (RR = 0.78, 95% CI = 0.70 to 0.86). No cost-effectiveness studies were identified. Conclusion Compared with usual care, comprehensive geriatric assessment was not associated with a difference in risk of mortality, hospitalization, treatment discontinuation, and dose reduction but was associated with a lower risk of treatment toxicity indicating its potential to optimize cancer treatment in this population. Further research is needed to evaluate cost-effectiveness. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Patterns, perceptions, and perceived barriers to physical activity in adult cancer survivors

Author

Eng, Lawson, Pringle, Dan, Su, Jie, Shen, XiaoWei, Mahler, Mary, Niu, Chongya, Charow, Rebecca, Tiessen, Kyoko, Lam, Christine, Halytskyy, Oleksandr, Naik, Hiten, Hon, Henrique, Irwin, Margaret, Pat, Vivien, Gonos, Christina, Chan, Catherine, Villeneuve, Jodie, Harland, Luke, Shani, Ravi M., Brown, M. Catherine, Selby, Peter, Howell, Doris, Xu, Wei, Liu, Geoffrey, Alibhai, Shabbir M. H., and Jones, Jennifer M.

Published
2018
Full Text
View/download PDF

33. Preference-based versus randomized controlled trial in prostate cancer survivors: Comparison of recruitment, adherence, attrition, and clinical outcomes

Author

Alibhai, Shabbir M. H., primary, Papadopoulos, Efthymios, additional, Durbano, Sara, additional, Tomlinson, George, additional, Mina, Daniel Santa, additional, Ritvo, Paul, additional, Sabiston, Catherine M., additional, Matthew, Andrew G., additional, Chiarotto, James, additional, Sidani, Souraya, additional, and Culos-Reed, S. Nicole, additional

Published
2022
Full Text
View/download PDF

34. Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review

Author

Hao, Qiukui, primary, Foroutan, Farid, additional, Han, Mi Ah, additional, Devji, Tahira, additional, Nampo, Fernando Kenji, additional, Mukherjee, Sudipto, additional, Alibhai, Shabbir M. H., additional, Rosko, Ashley, additional, Sekeres, Mikkael A., additional, Guyatt, Gordon H., additional, and Brignardello-Petersen, Romina, additional

Published
2022
Full Text
View/download PDF

45. The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.

Author

Papadopoulos, Efthymios, Wong, Andy Kin On, Law, Sharon Hiu Ching, Zhang, Lindsey Ze Jing, Breunis, Henriette, Emmenegger, Urban, and Alibhai, Shabbir M. H.

Subjects
SARCOPENIA, PROSTATE cancer, TREATMENT effectiveness, MUSCLE mass, WALKING speed, PROSTATE-specific antigen
Abstract

Introduction: Sarcopenia is common in men with metastatic castrate-resistant prostate cancer (mCRPC) and has been largely assessed opportunistically through computed-tomography (CT) scans, excluding measures of muscle function. Therefore, the impact of a comprehensive assessment of sarcopenia on clinical outcomes in men with mCRPC is poorly understood. The objectives of this study were to comprehensively assess sarcopenia through CT scans and measures of muscle function and examine its impact on severe treatment toxicity, time to first emergency room (ER) visit, disease progression, and overall mortality in men initiating chemotherapy or androgen receptor-targeted axis (ARAT) therapy for mCRPC. Methods: This was a secondary analysis of a prospective observational study of men with mCRPC at the Princess Margaret Cancer Centre between July 2015-May 2021. Participants were classified as sarcopenic if they had CT-based low muscle mass or low muscle density, a grip strength and gait speed score of <35.5kg and <0.8m/s, respectively, prior to treatment initiation. The impact of sarcopenia on severe treatment toxicity was assessed using multivariable logistic regression. Multivariable Cox regression models were used to determine the impact of sarcopenia on risk of visiting the ER, prostate-specific antigen progression, radiographic progression, and overall mortality. Results: A total of 110 men (mean age: 74.6) were included in the analysis. At baseline, 30 (27.3%) were classified as sarcopenic. Sarcopenia was a significant predictor of severe toxicity (aOR = 6.26, 95%CI = 1.17–33.58, P = 0.032) and ER visits (aHR = 4.41, 95%CI = 1.26–15.43, p = 0.020) in men initiating ARAT but not in men initiating chemotherapy. Sarcopenia was also a predictor of radiographic progression (aHR = 2.39, 95%CI = 1.06–5.36, p = 0.035) and overall mortality (aHR = 2.44, 95%CI = 1.17–5.08, p = 0.018) regardless of treatment type. Conclusions: Baseline sarcopenia predicts radiographic progression and overall mortality in men with mCRPC regardless of the type of treatment and may also predict severe treatment toxicity and ER visits in men initiating ARAT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results